التفاصيل البيبلوغرافية
| العنوان: |
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma |
| المؤلفون: |
Clingan, Philip, Ladwa, Rahul, Brungs, Daniel, Harris, Dean Laurence, McGrath, Margaret, Arnold, Susan, Coward, Jermaine, Fourie, Samuel, Kurochkin, Andriy, Malan, Daniel R, Mant, Andrew, Sharma, Vinay, Shue, Hong, Tazbirkova, Andrea, Berciano-Guerrero, Miguel-Angel, Charoentum, Chaiyut, Dalle, Stéphane, Dechaphunkul, Arunee, Dudnichenko, Oleksandr, Koralewski, Piotr, Lugowska, Iwona, Montaudié, Henri, Muñoz-Couselo, Eva, Sriuranpong, Virote, Oliviero, James, Desai, Jayesh |
| المساهمون: |
Checkpoint Therapeutics |
| المصدر: |
Journal for ImmunoTherapy of Cancer ; volume 11, issue 10, page e007637 ; ISSN 2051-1426 |
| بيانات النشر: |
BMJ |
| سنة النشر: |
2023 |
| الوصف: |
Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-related adverse events (AEs), indicating the need for improved therapies. Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody that activates innate and adaptive immunity by blocking PD-L1 interaction with PD-1 and B7-1 receptors. It is an unmodified immunoglobulin G1 subtype with a functional Fc domain capable of inducing antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Here, we present results of the pivotal study of patients with metastatic CSCC from an open-label, multicenter, multiregional, multicohort, phase 1 trial of cosibelimab. Methods In this trial, participants with metastatic CSCC received cosibelimab 800 mg intravenously every 2 weeks. Primary endpoint was objective response rate (ORR) by independent central review using Response Evaluation Criteria in Solid Tumors, V.1.1. Secondary endpoints included duration of response (DOR) and safety. Results Objective response was observed in 37 of 78 participants (47.4% (95% CI: 36.0% to 59.1%)), with median follow-up of 15.4 months (range: 0.4 to 40.5) as of data cut-off. Median DOR was not reached (range: 1.4+ to 34.1+ months), with response ongoing in 73.0% of participants. Common treatment-emergent AEs (≥15%) were fatigue (26.9%), rash (16.7%), and anemia (15.4%). Eighteen participants (23.1%) experienced immune-related AEs (grade 3: n=2 (2.6%); no grade 4/5). No treatment-related deaths were reported. Conclusions Cosibelimab demonstrated clinically meaningful ORR and DOR and was associated with a manageable safety profile. Trial registration number NCT03212404 . |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1136/jitc-2023-007637 |
| الإتاحة: |
https://doi.org/10.1136/jitc-2023-007637Test |
| حقوق: |
http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: |
edsbas.A0234120 |
| قاعدة البيانات: |
BASE |
